GW572016

DRUG3 trials

Sponsors

GlaxoSmithKline, Baylor Breast Care Center, University of New Mexico

Conditions

Breast CancerNeoplasms, Breast

Phase 1

INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients

WithdrawnNCT00455039

University of New MexicoBreast Cancer

Start: 2023-07-31End: 2023-07-31Updated: 2023-08-14

Phase 2

GW572016 For Treatment Of Refractory Metastatic Breast Cancer

CompletedNCT00062686

GlaxoSmithKlineNeoplasms, Breast

Start: 2003-11-30End: 2005-02-28Target: 200Updated: 2015-04-15

Neoadjuvant GW572016 to Treat Breast Cancer

CompletedNCT00206427

Baylor Breast Care CenterBreast Cancer

Start: 2004-08-31End: 2012-02-29Updated: 2021-09-29

Related Papers

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

Breast Cancer Research2017-07-2734 citations